Form 8-K - Current report:
SEC Accession No. 0001213900-24-080812
Filing Date
2024-09-23
Accepted
2024-09-23 08:06:24
Documents
14
Period of Report
2024-09-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0215344-8k_oramed.htm   iXBRL 8-K 27685
2 LETTER AGREEMENT, DATED AS OF SEPTEMBER 20, 2024, BY AND BETWEEN ORAMED PHARMACE ea021534401ex10-1_oramed.htm EX-10.1 26672
  Complete submission text file 0001213900-24-080812.txt   235514

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ormp-20240920.xsd EX-101.SCH 3009
4 XBRL LABEL FILE ormp-20240920_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ormp-20240920_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0215344-8k_oramed_htm.xml XML 3688
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 241314665
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)